drugset / Trial / NCT07065773

Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis

NCT07065773 ↗

Phase 2 Active not recruiting 50 enrolled Vanda Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open label study designed to evaluate the safety, tolerability, and efficacy of topically administered VTR-297 solution. The efficacy objectives of the study will be assessed using fungal culture testing, Neutral Red Staining (NRS) microscopy examination, and KOH microscopy examination after 4 weeks of treatment with VTR-297.

Timeline

Start
2025-05-05
Primary completion
2026-09
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Trichostatin A Unknown — Topical